Ultimately, further elucidation of the Notch1-Sox9 molecular pathway and its role in the maintenance of the ECM will lead to an improved mechanistic understanding of aortic valve calcification and development of novel therapeutic strategies for CAVD. This evidence concerns the gene SOX9 and congenital bilateral aplasia of vas deferens from CFTR mutation.